The design and construction of pre-filled syringes

American Pharmaceutical Review

Volumn 10, Issue 5, 2007, Pages

  Eakins, Michael N ^a  

^a Eakins and Associates

Author keywords

[No Author keywords available]

Indexed keywords

ALKENE; COPOLYMER; ETHYLENE; IODINATED CONTRAST MEDIUM; POLYETHER; POLYPROPYLENE; POLYSORBATE 80; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SERUM ALBUMIN; SILICONE; TUNGSTEN;

BIOTECHNOLOGICAL PRODUCTION; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG INDUSTRY; ELECTRON BEAM; GAMMA RADIATION; INFUSION PUMP; INSTRUMENT STERILIZATION; MATERIALS; MEDICAL SERVICE; SHELF LIFE; SHORT SURVEY; SYRINGE; VISCOSITY; WATER VAPOR;

EID: 55749101206     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. Harrison B, Rios M. Big shot: developments in pre-filled syringes. Pharm. Tech. May 2, 2007.
2. Detournay B et al. Prefilled disposable syringes vs conventional injection systems: European medicoeconomic analysis. Eur Hosp Pharm 4 (4): 109-113, 1998.
3. Contrast administration safety survey. Am Soc Radiologic Techologists Education and Research Foundation. January 2006.
4. Eakins MN. New plastics for old vials. BioProcess International 3: 52-58, 2005.
5. Statement of Jay P. Siegel M.D. Johnson & Johnson. Before the Senate Committee on Health, Education, Labor and Pensions. Followon Biologics. March 8, 2007.
6. Sharma B. et al. Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with Eprex. Eur J Hosp Pharm 5 (5): 86-91, 2004.
7. Boven K. et al. The increase incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 67 (6): 2346-2353, 2005.
8. Boven K. et al. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 20: Suppl 3: iii33-iii40, 2005.
9. Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nature Biotechnology 24 (6): 613-614, 2006.
10. Update on the actions by Johnson & Johnson Pharmaceutical Research & Development regarding erythropoietin antibody-positive pure red cell aplasia. http://www.jnjpharmarnd.com/company/ncasereports.html (accessed August 2007).
11. Osterberg RH. Potential toxicity of extractables and leachables in drug products. Am Pharm Rev 8 (2): 64-67, 2005.
12. Wen Z-Q et al. Investigation of contaminants in protein pharmaceuticals in pre-filled syringes by multiple micro-spectroscopies. Am Pharm Rev. 10 (5): 101-107, 2007.
13. ICH Topic Q 6 A. Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. CPMP/ICH/367/96. May 2000.
14. Overcashier DE, Chan EK, Hsu CC. Technical considerations in the development of pre-filled syringes for protein products. Am Pharm Rev 9 (7): 77-83, 2006.
15. MHRA Drug Alert Class 2 Medicines Recall. Reference MDR 03- 10/06. Neulasta® SureClick™ Injection Device. October 4, 2006.